| It is mandatory for any pharmaceutical manufacturer to get their products officially cleared or approved by the local Food and Drugs Administration-FDA authorities before introducing it into the market for public use. The FDA checks the efficacy and consequences of the product applied for. Once the product gets through such stringent norms then only the FDA certifies its approval through specific notification underlining product boundaries and usage recommendations which is strictly required to be adhered to both by the manufacturer and the practicing health care professionals.
The pill form of the drug called Baclofen-Lioresal too passed through such phase and was approved by the Food and Drugs Administration-FDA in the United States way back in November 1977. The FDA approved this oral drug as the skeletal muscle relaxant. The drug is the structural analog of the inhibitory neurotransmitter Gamma Amino Butyric Acid-GABA. The agency stated that clinically Baclofen-Lioresal is directed for use in treating spasticity and improve mobility in patients having multiple sclerosis and other spinal cord injuries working by reducing the number and severity of spasms besides relieving the related pains, clonus and muscle stiffness or rigidity.
Though mechanism of this drug was not completely understood, but it is supposed that drug works primarily at spinal cord levels by blocking polysynaptic afferent pathways and negligible levels of monosynaptic afferent pathways. Baclofen-Lioresal is also said to help improve bowel and bladder functions. The drug may reduce the transmission of impulses through such pathways by acting as inhibitory neurotransmitter or by hyperpolarizing the basic afferent nerve terminals which reduces the discharge of excitatory neurotransmitters like glutamate and aspartic acids.
|
